


Impact Report


ALCMI

ADDARIO LUNG CANCER MEDICAL INSTITUTE

2025

A microscopic image of lung tissue stained with hematoxylin and eosin (H&E). The image shows a dense cluster of purple-stained nuclei, likely representing a tumor or a large area of inflammation, set against a background of pink-stained connective tissue and other cellular structures. A white rectangular text box is overlaid on the upper portion of the image.

It's estimated that 226,650 people were diagnosed with lung cancer this year in the United States.

A microscopic image of lung tissue stained with hematoxylin and eosin (H&E). The image shows a dense cluster of purple-stained nuclei, likely representing a tumor or a large area of inflammation, set against a background of pink-stained connective tissue and other cellular structures. A white rectangular text box is overlaid on the lower portion of the image.

This 2025 report provides an overview of how we fought back.

An Enduring Vision

This year marked a crucial chapter in the history of the Addario Lung Cancer Medical Institute (ALCMI), a year defined by both significant loss and remarkable progress.

With the passing of our visionary founder, Bonnie J. Addario, we mourned a leader whose relentless drive transformed the landscape of lung cancer research. Yet even in grief, we found renewed energy and purpose.

Bonnie's legacy is one of hope and action. Therefore, we are moving forward with bold collaborations and new trials that accelerate discoveries and improve patient outcomes.

Her founding vision—to unite academia, industry, clinicians, and patient advocates—continues to guide our work.

In 2025, we advanced that vision with measurable impact. We launched and expanded decentralized, investigator-initiated trials that are reshaping how lung cancer research is conducted.

Our INHERIT and SUCCEED clinical trials, developed in partnership with leading institutions like Dana-Farber Cancer Institute and GO2 for Lung Cancer, are uncovering critical insights into hereditary risk and small cell lung cancer, respectively.



Bonnie J. Addario

For our partners in biotech and pharma, ALCMI offers a unique opportunity to collaborate within a nimble, patient-centered ecosystem that delivers high-quality data and accelerates therapeutic innovation. And we get better every day.

Bonnie believed that lung cancer could become a chronically managed disease within our lifetime. In 2025, we moved closer to that reality.

The future of ALCMI is strong, focused, and poised for acceleration, and we thank you for being part of Bonnie's vision.

A blue ink signature of Dr. Ken Krantz, written in a cursive style.

DR. KEN KRANTZ
Chairman and CEO

Stewards of Hope

Bonnie J. Addario's legacy is defined not only by her advocacy but also by the scientific priorities that continue to guide ALCMI's mission.

In 2025, we advanced the areas of research that most inspired her, translating vision into action across three strategic pillars:

Young Lung Cancer

Bonnie recognized early on that lung cancer in younger patients is under-researched and often misunderstood. So, we launched the Epidemiology of Young Lung Cancer study and are preparing to release significant findings in 2026.

We are deepening our commitment to this population by expanding molecular profiling, investigating environmental and genetic risk factors, and building targeted registries to support precision medicine approaches for early-onset disease.

Hereditary Risk Factors

Bonnie's determination to understand familial patterns of lung cancer laid the foundation for our INHERIT study—a first-of-its-kind effort to uncover inheritable genetic markers and inform screening strategies for at-risk families. This work is reshaping how we think about prevention and early detection.



Bonnie and Tony Addario

Collaboration and Empowerment

Bonnie believed that scientists should be empowered to lead. The SUCCEED trial exemplifies this principle as a decentralized, investigator-initiated study focused on small cell lung cancer, designed to ultimately improve access to trials and outcomes in a historically underserved patient population.

The momentum captured in this report reflects Bonnie's founding principles—collaboration, urgency, and scientific excellence.

We honor her memory not only by continuing her work, but by expanding it with the same boldness and clarity of purpose that she championed.

RICHARD ERWIN
COO, Executive Director,
and Board Member

Our Story

Our Mission

At the Addario Lung Cancer Medical Institute (ALCMI), we believe some of the most promising clinical trial concepts originate within academic institutions, driven by clinician-scientists who see the unanswered questions every day. That's why, as a nonprofit organization, we've made it our mission to support investigator-initiated clinical trials from inception to completion.

As a 501 (c) (3) nonprofit organization, we're dedicated to advancing research that can lead to new therapeutics, diagnostics, and a better understanding of lung cancer risk factors and resistance mechanisms.

We administer and support clinical trials with a full slate of clinical trial operations capabilities.

We bridge the gap between clinical research organizations (CROs) and site management organizations (SMOs), resulting in a streamlined, agile process for quickly funding and initiating lung cancer research projects.

We offer our partners expertise, collaboration, and speed.

Our Specialty

We specialize in observational, biomarker, resistance mechanism, and biospecimen collection trials. We accomplish these using either a fully remote, decentralized approach, a traditional multi-center setting, or a hybrid technique that combines best practices and advanced technologies to support the effort.

In addition, our staff brings over 30 years of experience in designing and managing Phase 1-4 interventional therapeutic trials, adhering to established ICH/GCP and FDA standards.

Research
projects
launched
to date

24

At a glance

2025



463

Study contacts



248

Subjects enrolled



233

Biospecimens collected



Trial Management

5 Active trials

3 Trials closed to new enrollment

1 New trial launched

Conference Exhibitions

2 Exhibits

7 New study proposals submitted

Social Media

76,571 LinkedIn impressions

1,089 LinkedIn followers

6.3% Engagement rate

Website Statistics

58,000 page views

+196% increase in active users


+186% growth in sessions



Epidemiology of Young Lung Cancer

This study seeks to better understand why young people are developing lung cancer. Specifically, we are studying environmental exposures and other risk factors.

In 2024, researchers presented data at the World Lung Conference showing that young lung cancer patients eat healthier diets—richer in leafy greens, whole fruits, and whole grains—than the average American. This year, we confirmed that data, which raises concern about a possible dietary link to lung cancer in young people.



At the 2026 American Association for Cancer Research annual meeting, researchers will present new findings that suggest a possible connection between a class of carcinogens and their mechanism of action. These insights may help explain why some young individuals who follow healthy diets develop lung cancer at higher rates than their peers without the disease.

1985


The year smoking rates peaked in the US.



However, lung cancer rates for women have not fallen.

“We used to say we did research in the laboratory or we did translational work in the clinic. Now, with studies like this, we have the opportunity to make an observation and then go back and do laboratory studies to understand that observation.”


Dr. Jorge J. Nieva,
USC Norris
Comprehensive
Cancer Center




Small Cell Study (SUCCEED)

This feasibility study seeks to assess the effectiveness of a remote, decentralized strategy for enrolling participants, collecting online surveys, and collecting blood samples among people with extensive-stage small cell lung cancer, a particularly difficult patient population to study.

The study launched in June 2025 with the goal of enrolling 30 patients.



Enrollment Completion



7.5K
study landing page views

97
form submissions

“In order to best serve patients with small cell lung cancer, the SUCCEED study will seek to learn about patient preferences and goals. We will do so in a unique way, bringing the study to the patient so that patients can join while being close to home, hopefully making it easier for them to take part.”

Dr. Christine Lovly, City of Hope




2025 Conference Scrapbook



INHERIT

This study aims to better understand the genetic risk, or predisposition, for developing lung cancer. Researchers are also learning more about the specific lung cancers that develop in people who may have inherited risk. Environmental factors and their interplay with genetics are also being explored. The end goal is to improve lung cancer screening, prevention, and treatment.


This trial expands on earlier ALCMI research that identified one specific inherited genetic mutation in the EGFR gene.



<p>235</p> <p>blood samples collected.</p>	<p>83%</p> <p>of cohort 1 with familial EGFR mutation interested in CT scan.</p>
<p>63%</p> <p>of participants report no prior lung cancer diagnosis.</p>	<p>82%</p> <p>of enrollees are women</p>

“Even participants without EGFR mutations are grateful that we’re finally investigating the hereditary causes of lung cancer that have affected their families for generations. We’re honored to partner with them and look forward to offering CT screening to participants who don’t currently meet standard eligibility criteria.”

Dr. Jaclyn LoPiccolo,
Dana-Farber
Cancer Institute




SPARK

Studying KRAS resistance.
NCT05272423

This study is evaluating new mutations that develop after treatment with targeted therapies in patients with KRAS cancers.

In September 2025, enrollment was closed after investigators found a previously unknown mutation.

The study team is currently confirming its data and preparing to submit abstracts to conferences in 2026.




ENIGMA

Studying ALK+ resistance.
NCT04881916

This study aims to obtain and study tumor and saliva specimens from patients with advanced ALK-positive lung cancer, as well as to collect clinical information. The overall goal is to enhance understanding of the biology of ALK-positive lung cancer.

In September 2025, enrollment was closed. The study team is currently confirming its data and preparing to submit abstracts to conferences in 2026.



Thank you to all the courageous and generous patients who are participating in our trials, and to the patient advocates who stand by them in their battle against this disease!

Board of Directors

Tony Addario
Steve Cavan
Richard Erwin
Bruce Gellman
Dr. Gary Ingenito
Dr. Ken Krantz
Tom Krohn

ALCMI Staff

Debi Beltramo
Richard Erwin
Allison Harper
Ericka Izzo
Virginia Kotait
Dr. Ken Krantz
Wayne Niemi

Scientific Leadership Board

Tony Addario
Dr. Benjamin Besse
Dr. Trever Bivona
Dr. David Carbone
Dr. David Gandara
Dr. David Jablons
Dr. Pasi A. Jänne
Dr. Ita Laird-Offringa
Dr. Christine Lovly
Dr. Harvey Pass
Dr. Jonathan Riess
Dr. Giorgio V. Scagliotti

Addario Lung Cancer Medical Institute
1100 Industrial Road, Suite 1
San Carlos, CA 94070
(650) 598-2857
alcmi.org

ALCMI

ADDARIO LUNG CANCER MEDICAL INSTITUTE